Skip to content

For US Healthcare Professionals Only

Prescribing Information

Patient Site

Works Fast To deliver results

VEVYE® shows clinically meaningful and statistically significant improvement in total corneal fluorescein staining (tCFS) by Day 15 in clinical studies.^5-6

Works Fast To deliver results

VEVYE® shows clinically meaningful and statistically significant improvement in total corneal fluorescein staining (tCFS) by Day 15 in clinical studies.^5-6

Signs

Symptoms

Primary Endpoint Data

ESSENCE-1 and -2 Studies Measuring Change from Baseline in tCFS ^5-6

NEI* Scale (0-15)

In pooled clinical studies

56.8%

of patients achieved 3 or more grades of improvement in tCFS  at Day 15.

ESSENCE-1:

VEVYE

Perfluorobutylpentane

ESSENCE-2:

VEVYE

Perfluorobutylpentane

ESSENCE-1 and -2 Studies Measuring Change from Baseline in tCFS ^5-6

NEI* Scale (0-15)

Swipe to view More

ESSENCE-1:

VEVYE

Perfluorobutylpentane

ESSENCE-2:

VEVYE

Perfluorobutylpentane

*National Eye Institute

VEVYE® is shown to be

Comfortable and Well‑tolerated ^1,5‑7

See Safety Data

See the Improvement

The case studies above show real world patients. Names and images have been changed to protect privacy.

Sustained Efficacy ⁷

VEVYE demonstrated sustained improvement over 12 months in both the signs and symptoms of dry eye disease.

Total Corneal Fluorescein Staining (tCFS)

Mean Scores (Grade, NEI* Scale)

Mean Scores (Grade, NEI* Scale)

Tear Production

Mean Schirmer’s
Tear Scores (mm)

Mean Schirmer’s
Tear Scores (mm)

*National Eye Institute. 0-15 Scale

Pushing Efficacy Beyond Conventional Standards ⁹

In a Phase 2 Study to evaluate efficacy, safety and tolerability

VEVYE showed a statistically significant difference when compared to Restasis ^® (cyclosporine ophthalmic emulsion) 0.05% at Day 29 and Day 85.

Restasis (CsA 0.05%)

Perfluorobutylpentane

VEVYE

Phase 2 Head-to-Head Study Measuring Change from Baseline in tCFS

NEI* Scale (0-15)

This was a dose ranging study. Restasis ^® was evaluated head-to-head as an open label comparator.

In a Phase 2 Study to evaluate efficacy, safety and tolerability

VEVYE showed a statistically significant difference when compared to Restasis ^® (cyclosporine ophthalmic emulsion) 0.05% at Day 29 and Day 85.

Phase 2 Head-to-Head Study Measuring Change from Baseline in tCFS

NEI* Scale (0-15)

Swipe to view More

Restasis (CsA 0.05%)

Perfluorobutylpentane

VEVYE

This was a dose ranging study. Restasis ^® was evaluated head-to-head as an open label comparator.

*National Eye Institute. **= p <0.05 vs Restasis®

Continue to Symptoms Data

time to try vevye

Connect with a representative to learn more.

Connect with a representative to learn more.

Contact Us

INDICATION AND USAGE

VEVYE® (cyclosporine ophthalmic solution) 0.1% is indicated for the treatment of the signs and symptoms of dry eye disease.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Potential for Eye Injury and Contamination – To avoid the potential for eye injury and/or contamination, patients should not touch the bottle tip to the eye or other surfaces.
Use with Contact Lenses – VEVYE should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following the administration of VEVYE.

Adverse Reactions

In clinical trials with 738 subjects receiving at least 1 dose of VEVYE, the most common adverse reactions were instillation site reactions (8%) and temporary decreases in visual acuity (3%).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. For additional information about VEVYE, please see the Full Prescribing Information.